Literature DB >> 9705602

Antioxidants and mucosa protectives: realistic therapeutic options in inflammatory bowel disease?

L Kruidenier1, H W Verspaget.   

Abstract

Oxidative damage is involved in the pathogenic process of idiopathic chronic inflammatory bowel disease. Although specific intervention in the oxidative cascade showed promising results in animal models and preliminary patient trials, the clinical efficacy of antioxidants still has to be established. Mucosa protection, for example by dietary fatty acids, seems to attenuate the intestinal inflammatory process as well but awaits definite clinical proof for the treatment of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705602      PMCID: PMC1781836          DOI: 10.1080/09629359891081

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  18 in total

1.  Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in treatment of Crohn's disease.

Authors:  J Emerit; S Pelletier; D Tosoni-Verlignue; M Mollet
Journal:  Free Radic Biol Med       Date:  1989       Impact factor: 7.376

2.  Effect of lecithinized-superoxide dismutase on the rat colitis model induced by dextran sulfate sodium.

Authors:  Y Hori; J Hoshino; C Yamazaki; T Sekiguchi; S Miyauchi; S Mizuno; K Horie
Journal:  Jpn J Pharmacol       Date:  1997-05

Review 3.  Short-chain fatty acids in ulcerative colitis.

Authors:  Y I Kim
Journal:  Nutr Rev       Date:  1998-01       Impact factor: 7.110

Review 4.  Nutrition and ulcerative colitis.

Authors:  A Burke; G R Lichtenstein; J L Rombeau
Journal:  Baillieres Clin Gastroenterol       Date:  1997-03

5.  Impairment of antioxidants in colonic epithelial cells isolated from trinitrobenzene sulphonic acid-induced colitis rats. Protective effect of rebamipide.

Authors:  W L Zea-Iriarte; K Makiyama; S Goto; K Murase; Y Urata; I Sekine; K Hara; T Kondo
Journal:  Scand J Gastroenterol       Date:  1996-10       Impact factor: 2.423

6.  Effect of Z-103 on TNB-induced colitis in rats.

Authors:  T Yoshikawa; T Yamaguchi; N Yoshida; H Yamamoto; S Kitazumi; S Takahashi; Y Naito; M Kondo
Journal:  Digestion       Date:  1997       Impact factor: 3.216

7.  Role of reactive oxygen metabolites in experimental colitis.

Authors:  A Keshavarzian; G Morgan; S Sedghi; J H Gordon; M Doria
Journal:  Gut       Date:  1990-07       Impact factor: 23.059

8.  Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease.

Authors:  A Belluzzi; C Brignola; M Campieri; A Pera; S Boschi; M Miglioli
Journal:  N Engl J Med       Date:  1996-06-13       Impact factor: 91.245

9.  The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats.

Authors:  G Yue; F F Sun; C Dunn; K Yin; P Y Wong
Journal:  J Pharmacol Exp Ther       Date:  1996-01       Impact factor: 4.030

10.  Effect of liposomal-encapsulated superoxide dismutase on active oxygen-related human disorders. A preliminary study.

Authors:  Y Niwa; K Somiya; A M Michelson; K Puget
Journal:  Free Radic Res Commun       Date:  1985
View more
  3 in total

Review 1.  Clinical implications of oxidative stress and antioxidant therapy.

Authors:  Gerald W Dryden; Ion Deaciuc; Gavin Arteel; Craig J McClain
Journal:  Curr Gastroenterol Rep       Date:  2005-08

2.  Experimental ulcerative colitis impairs antioxidant defense system in rat intestine.

Authors:  N Nieto; M I Torres; M I Fernández; M D Girón; A Ríos; M D Suárez; A Gil
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

3.  Intestinal anti-inflammatory activity of Ground Cherry (Physalis angulata L.) standardized CO2 phytopharmaceutical preparation.

Authors:  Luiz Domingues Almeida Junior; Ana Elisa Valencise Quaglio; Celso Acácio Rodrigues de Almeida Costa; Luiz Claudio Di Stasi
Journal:  World J Gastroenterol       Date:  2017-06-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.